DeuterOncology NV was founded in September 2020 by Dr Timothy Perera in Flanders, Belgium. Developer of MET inhibitors intended to optimize oncology treatments and outcomes. The company's lead compound is a dual MET and RAS pathway inhibitor under pre-clinical investigation as a targeted therapy for lung cancer, as well as potential broader oncology applications when used in combination with other SOC and targeted agents, enabling the medical community to treat cancer patients effectively.
DeuterOncology NV was founded in September 2020 by Dr Timothy Perera in Flanders, Belgium. Developer of MET inhibitors intended to optimize oncology treatments and outcomes. The company's lead compound is a dual MET and RAS pathway inhibitor under pre-clinical investigation as a targeted therapy for lung cancer, as well as potential broader oncology applications when used in combination with other SOC and targeted agents, enabling the medical community to treat cancer patients effectively.
